DekaBank Deutsche Girozentrale Sells 725 Shares of Enovis Corporation $ENOV

DekaBank Deutsche Girozentrale trimmed its holdings in shares of Enovis Corporation (NYSE:ENOV) by 36.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,256 shares of the company’s stock after selling 725 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Enovis were worth $40,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. T. Rowe Price Investment Management Inc. lifted its position in shares of Enovis by 0.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 6,207,768 shares of the company’s stock worth $237,199,000 after purchasing an additional 44,632 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Enovis by 11.3% during the first quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company’s stock worth $233,356,000 after purchasing an additional 621,069 shares during the last quarter. DAVENPORT & Co LLC lifted its position in shares of Enovis by 10.4% during the first quarter. DAVENPORT & Co LLC now owns 3,071,985 shares of the company’s stock worth $116,489,000 after purchasing an additional 289,644 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Enovis by 1.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,927,340 shares of the company’s stock worth $111,852,000 after purchasing an additional 27,894 shares during the last quarter. Finally, Royce & Associates LP lifted its position in shares of Enovis by 0.8% during the first quarter. Royce & Associates LP now owns 2,490,806 shares of the company’s stock worth $95,174,000 after purchasing an additional 20,230 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.

Insider Transactions at Enovis

In other Enovis news, CEO Damien Mcdonald purchased 6,457 shares of the company’s stock in a transaction dated Thursday, September 11th. The shares were acquired at an average price of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the purchase, the chief executive officer owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. The trade was a 6.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Bradley J. Tandy purchased 3,200 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were acquired at an average price of $31.41 per share, for a total transaction of $100,512.00. Following the purchase, the senior vice president directly owned 43,515 shares of the company’s stock, valued at approximately $1,366,806.15. The trade was a 7.94% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 12,157 shares of company stock worth $374,760. Insiders own 2.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ENOV shares. Evercore ISI decreased their target price on Enovis from $48.00 to $46.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. UBS Group decreased their price objective on Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a report on Friday, August 8th. Wells Fargo & Company decreased their price objective on Enovis from $48.00 to $41.00 and set an “overweight” rating for the company in a report on Friday, August 8th. Canaccord Genuity Group decreased their price objective on Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a report on Friday, August 8th. Finally, Needham & Company LLC decreased their price objective on Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Enovis Price Performance

ENOV opened at $32.91 on Tuesday. The business’s 50-day moving average is $31.30 and its two-hundred day moving average is $31.54. Enovis Corporation has a 1 year low of $25.47 and a 1 year high of $49.83. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The firm has a market capitalization of $1.88 billion, a PE ratio of -2.31 and a beta of 1.69.

Enovis (NYSE:ENOV) last posted its earnings results on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company had revenue of $383.81 million for the quarter. Research analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.